Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for P3 Health Partners (PIII) over the last 5 years, with Q3 2025 value amounting to $2.5 million.

  • P3 Health Partners' Gains from Investment Securities rose 14427.4% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 18580.88%. This contributed to the annual value of -$22.1 million for FY2024, which is 40620.33% down from last year.
  • Latest data reveals that P3 Health Partners reported Gains from Investment Securities of $2.5 million as of Q3 2025, which was up 14427.4% from -$2.0 million recorded in Q2 2025.
  • P3 Health Partners' Gains from Investment Securities' 5-year high stood at $14.3 million during Q1 2025, with a 5-year trough of -$11.8 million in Q2 2022.
  • For the 5-year period, P3 Health Partners' Gains from Investment Securities averaged around -$779499.6, with its median value being -$485500.0 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 65986.75% in 2024, then skyrocketed by 674120.37% in 2025.
  • Quarter analysis of 5 years shows P3 Health Partners' Gains from Investment Securities stood at -$5.5 million in 2021, then dropped by 17.45% to -$6.5 million in 2022, then surged by 192.73% to $6.0 million in 2023, then tumbled by 224.63% to -$7.5 million in 2024, then skyrocketed by 133.92% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, -$2.0 million for Q2 2025, and $14.3 million during Q1 2025.